Berberrubine and its analog, hydroxypropyl‐berberrubine, regulate LDLR and PCSK9 expression via the ERK signal pathway to exert cholesterol‐lowering effects in human hepatoma HepG2 cells
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Berberine (BBR), the major isoquinoline alkaloid in Chinese herb Rhizoma coptidis, has significant lipid‐lowering effect by upregulating hepatic low‐density lipoprotein receptor (LDLR) expression. In a previous study, we have indicated that berberrubine (M3), a major metabolite of BBR in vivo, displays the most potential hypolipidemic effects via upregulating LDLR expression in human hepatoma (HepG2) cells compared with BBR and 3 other metabolites. Accordingly, 9 M3 analogs (A1‐A9) were modified at the C9 position. We aimed to find a new promising agent by evaluating the cholesterol‐lowering effect and clarifying the related molecular mechanism. In the current study, the cellular cholesterol content was assayed with a commercial cholesterol assay kit. Real‐time polymerase chain reaction and Western blot assay were used to explore the molecular mechanism of M3 and its analogs on the hypolipidemic effect. Among M3 and its analogs, hydroxypropyl‐berberrubine (A8) exhibited the highest potential effects on the upregulation of LDLR expression, which was accompanied by a steady decline of proprotein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA and protein levels. Furthermore, inhibition of extracellular signal‐regulated kinase (ERK) activity with PD98059 prevented the upregulation of LDLR and downregulation of PCSK9 induced by A8. The current study revealed that M3 and its structurally modified analog, A8, could regulate hepatic LDLR and PCSK9 expression to exert lipid‐lowering effects via the ERK signal pathway, while A8 showed a stronger effect and might be a promising drug candidate against hyperlipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · cited 1×
“Conversely, loss‐of‐function mutations within PCSK9 are associated with a reduction in plasma LDL‐C and protection against coronary heart disease.(16,17) Thus, PCSK9 levels directly influence the level of circulating LDL‐C.”
BackgroundZhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788 · cited 4×
“A extracellular domain of hepatic LDLR.13,14 This binding and the subsequent internalization of the PCSK9‐LDLR complex lead to the intracellular degradation of LDLR in lysosomes, thus increasing the level of circulating LDL‐ C.”
BackgroundInfluentialNabel, E. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035098 · Cited by 431
Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein
Packard, C. J. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311066 · Cited by 225
The involvement of P-glycoprotein in berberine absorption
Pan, G., Wang, G., Liu, X., Fawcett, J. P., & Xie, Y. (2002) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2002.t01-1-910403.x · Cited by 225
P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers
Maeng, H.-J., Yoo, H.-J., Kim, I.-W., Song, I.-S., Chung, S.-J., & Shim, C.-K. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10268 · Cited by 128
Zhou, Y., Cao, S., Wang, Y., Xu, P., Yan, J., Bin, W., Qiu, F., & Kang, N. (2014) · Fitoterapia · doi:10.1016/j.fitote.2013.11.010 · Cited by 81
Self-citation
Cited by
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Šmejkal, K., Malaník, M., et al. (2019) · Theranostics · doi:10.7150/thno.30787 · Cited by 465
Yang, L., Zhu, W., Zhang, X., Zhou, X., Wu, W., & Shen, T. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154716 · Cited by 34
Mechanisms of action and therapeutic potential of PCSK9-regulating drugs
Qi, C., Fan, D., Wang, L., Guo, L., Jiang, H., & Wang, L. (2025) · Pharmaceutical Biology · doi:10.1080/13880209.2025.2514021 · Cited by 7
Metadata
- Authors
- Cao, S., Xu, P., Yan, J., Liu, H., Liu, L., Cheng, L., Qiu, F., & Kang, N.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2018-10-18
- Volume
- 120
- Issue
- 2
- Pages
- 1340-1349
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2897945980
- Cited by
- 56
- References
- 10
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.